Genetic Systems division non-GAAP revenue was $235 million in the second quarter, an increase of 5 percent over the same period last year. Excluding the impact from currency and the completed divestiture of the SQL*LIMS business, organic revenue growth was 7 percent. This increase was a result of strong double-digit growth in next generation sequencing and mid single-digit growth in capillary electrophoresis instruments and reagents sold to research and clinical labs.Technology highlights include:The approval by the United States Federal Bureau of Investigation of Identifiler?® Direct and Identifiler?® Plus forensic kits. These kits are for use by laboratories generating DNA profiles for inclusion in the National DNA Index System (NDIS) CODIS Database. The advanced capabilities of these new forensic kits enables a new era of efficiency and effectiveness for forensic DNA laboratories. Molecular Biology Systems division non-GAAP revenue was $434 million in the second quarter, an increase of approximately 6 percent over the same period last year. Organic revenue growth was 2 percent, excluding the impact from currency and acquisitions, and 6 percent excluding the impact of currency, acquisitions and H1N1 sales. Growth was a result of robust demand for genomic assays and strong growth in the Molecular Biology Reagents business.Technology highlights include:The acquisition of a majority stake in Geneart AG, the global leader of the synthetic gene market segment. The combination of Geneart with Life Technologies' resources and commercial capabilities will create a well-capitalized synthetic biology company with advanced technology and production capabilities, providing products to fuel innovation in this emerging field. Cell Systems division non-GAAP revenue was $230 million in the second quarter, an increase of 13 percent over the same period last year. Excluding the impact from currency, organic revenue growth was also 13 percent year over year. This growth was a result of strong demand across the portfolio, including robust growth in the Primary Stem Cell, Beads Based Separation and BioProduction business.Technology highlights include:The announcement of a collaboration between the University of California, San Diego, The Salk Institute for Biological Studies and Life Technologies to initiate cell transplant therapy studies for ALS. Along with the Company's recent introduction of the Gibco?® CTS product platform, the collaboration is part of a broader effort to help researchers expedite promising cell-based therapies. Regional organic growth rates for the quarter compared to the same quarter of the prior year were as follows: the Americas increased 7 percent, Europe 4 percent, Asia Pacific 19 percent. Japan declined 4 percent. Revenue from orders transacted through Life Technologies' eCommerce channels grew 14 percent during the quarter. Approximately 52 percent of all transactions are now processed using eCommerce platforms.

Fiscal Year 2010 Outlook

Subject to the risk factors detailed in the Safe Harbor Statement section of this release, the company updated its expectations for fiscal year 2010 financial performance. Organic revenues are expected to increase in the mid- to high-single digits and full year non-GAAP earnings per share are expected to be between $3.35 to $3.50. The company will provide further detail on its business outlook during the conference call today.

SOURCE Life Technologies Corporation